

L.N. 104 of 2021

Pharmacy and Poisons (Amendment) Regulation 2021

(Made by the Pharmacy and Poisons Board under section 29(1B) of the Pharmacy and Poisons Ordinance (Cap. 138) subject to the approval of the Secretary for Food and Health)

1. Pharmacy and Poisons Regulations amended

The Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) are amended as set out in sections 2, 3 and 4.

2. Schedule 1 amended (substances to which certain restrictions with respect to the sale, supply, labelling and storage apply under regulations 3, 5, 6, 22 and 24)

(1) Schedule 1, Division A, after item “Avanafil; its salts”—

Add

“Avapritinib; its salts”.

(2) Schedule 1, Division A, after item “Fotemustine; its salts”—

Add

“Fremanezumab”.

(3) Schedule 1, Division A, after item “Gemtuzumab ozogamicin”—

Add

“Gilteritinib; its salts”.

(4) Schedule 1, Division A, after item “Imiquimod; its salts”—

Add

“Inclisiran; its salts”.

- (5) Schedule 1, Division A, after item “Lamotrigine; its salts”—

Add

“Lanadelumab”.

- (6) Schedule 1, Division A, after item “Oxytocins”—

Add

“Ozanimod; its salts”.

- (7) Schedule 1, Division A, after item “Rasburicase; its salts”—

Add

“Ravulizumab”.

- (8) Schedule 1, Division A, after item “Ticlopidine; its salts”—

Add

“Tildrakizumab”.

- (9) Schedule 1, Division A, after item “2,2,2-Trichloroethyl alcohol, esters of; their salts”—

Add

“Trifarotene; its salts; its esters; their salts”.

3. Schedule 3 amended (substances required by regulation 9 to be sold by retail only upon a prescription given by a registered medical practitioner, registered dentist or registered veterinary surgeon)

- (1) Schedule 3, Division A, after item “Avanafil; its salts”—

Add

“Avapritinib; its salts”.

- (2) Schedule 3, Division A, after item “Fotemustine; its salts”—

Add

“Fremanezumab”.

- (3) Schedule 3, Division A, after item “Gemtuzumab ozogamicin”—

Add

“Gilteritinib; its salts”.

- (4) Schedule 3, Division A, after item “Imiquimod; its salts”—

Add

“Inclisiran; its salts”.

- (5) Schedule 3, Division A, after item “Lamotrigine; its salts”—

Add

“Lanadelumab”.

- (6) Schedule 3, Division A, after item “Oxytocins”—

Add

“Ozanimod; its salts”.

- (7) Schedule 3, Division A, after item “Rasburicase; its salts”—

Add

“Ravulizumab”.

- (8) Schedule 3, Division A, after item “Ticlopidine; its salts”—

Add

“Tildrakizumab”.

- (9) Schedule 3, Division A, after item “2,2,2-Trichloroethyl alcohol, esters of; their salts”—

Add

“Trifarotene; its salts; its esters; their salts”.

4. Schedule 10 amended (Poisons List)

- (1) Schedule 10, section 2, Table, Part 1, Division A, after item “Avanafil; its salts”—

Add

“Avapritinib; its salts”.

- (2) Schedule 10, section 2, Table, Part 1, Division A, after item “Fotemustine; its salts”—

Add

“Fremanezumab”.

- (3) Schedule 10, section 2, Table, Part 1, Division A, after item “Gemtuzumab ozogamicin”—

Add

“Gilteritinib; its salts”.

- (4) Schedule 10, section 2, Table, Part 1, Division A, after item “Imiquimod; its salts”—

Add

“Inclisiran; its salts”.

- (5) Schedule 10, section 2, Table, Part 1, Division A, after item “Lamotrigine; its salts”—

Add

“Lanadelumab”.

- (6) Schedule 10, section 2, Table, Part 1, Division A, after item “Oxytocins”—

Add

“Ozanimod; its salts”.

- (7) Schedule 10, section 2, Table, Part 1, Division A, after item “Rasburicase; its salts”—

Add

“Ravulizumab”.

- (8) Schedule 10, section 2, Table, Part 1, Division A, after item “Ticlopidine; its salts”—

Add

“Tildrakizumab”.

- (9) Schedule 10, section 2, Table, Part 1, Division A, after item “2,2,2-Trichloroethyl alcohol, esters of; their salts”—

Add

“Trifarotene; its salts; its esters; their salts”.

Dr. Constance CHAN
Chairman,
Pharmacy and Poisons Board

18 June 2021

Explanatory Note

This Regulation amends the following provisions of the Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) (*specified provisions*)—

- (a) Division A of Schedule 1;
- (b) Division A of Schedule 3; and
- (c) Division A of Part 1 of the Poisons List set out in Schedule 10.

2. The substances listed in the specified provisions are subject to specific requirements concerning sale, supply, labelling and storage. The Regulation adds certain substances to the specified provisions. Main effects of the amendments include—

- (a) that the sale, by retail, of the newly added substances—
 - (i) may only be effected on the registered premises of an authorized seller of poisons by a registered pharmacist or in the presence and under the supervision of a registered pharmacist; and
 - (ii) may only be effected on and in accordance with a prescription by a registered medical practitioner, registered dentist or registered veterinary surgeon; and
- (b) that the newly added substances, if stored in retail premises, must be stored in a part of the premises to which customers are not permitted access.